Recombinant human erythropoietin (rHuEpo) has been shown to be effective in correcting the anemia of chronic renal failure, but the dose needed may be variable. The reason for this variation is not known, but several factors could be involved, such as iron deficiency, inflammation, aluminum intoxication, hyperparathyroidism, blood losses, or marrow dysfunction. Treatment with rHuEpo was given intravenously thrice weekly after hemodialysis to 64 consecutive unselected patients with the anemia of chronic renal failure. The starting dose was 50 U/kg/dose, which was increased to 75 and 100 U/kg/dose if no response was observed after 1 and 2 months of treatment. After a minimum follow-up of 6 months, response was evaluated as early (hematocrit [Hct] 230% before 3 months) or late (Hct 230% after 3 months) response, or failure (target Hct not attained). We examined the value of various laboratory parameters (baseline values and early changes) as predictors of response to rHuEpo. The best prediction by pretreatment parameters only was obtained with baseline serum transferrin receptor (TfR) ( < or 23,500 ng/mL) and fibrinogen ( < or 2 4 g/L): 100% response rate when both parameters were low, versus only 29% when they were both high, and versus 67% when one was low and the NEMIA IS a predictable feature of chronic renal failure A and many patients on hemodialysis require red blood cell transfusions. The primary mechanism of this anemia is inadequate erythropoietin (Epo) production by the kidney.' However, other factors are involved, such as repeated blood loss in the dialyser, shortened red blood cell life span, aluminum intoxication, and hyperparathyroidism.2 Clinical trials in renal failure patients on hemodialysis showed that recombinant human erythropoietin (rHuEpo) was effective in correcting the anemia and eliminating the need for transfus i o n~.~~~
other high. When the 2-week TfR increment was greater than 20%, the response rate was 96%. When TfR increment was less than 20%. the response rate was 100% when baseline TfR and fibrinogen were low, 12% when fibrinogen was elevated, and 62% when fibrinogen was low but baseline TfR high. The predictive value of baseline TfR and fibrinogen and of the 2-week increment of TfR was confirmed by life table analysis and stepwise discriminant analysis. Major reasons for failure or late response were identified and included subclinical inflammation, iron deficiency, functional iron deficiency, marrow disorders, hemolysis, bleeding, and low Epo dose. We conclude that response to rHuEpo can be predicted early by pretreatment fibrinogen and TfR, together with early changes of TfR levels. These prognostic factors illustrate the importance of the early erythropoietic response, subclinical inflammation, and functional iron deficiency. Early recognition of a low probability of response in a given patient could help identify and correct specific causes of treatment failure to hasten clinical improvement and avoid prolonged ineffective use of an expensive medication. U/kg."6 The reasons for this variation in response rates are not known but several factors could be involved, such as iron deficiency, inflammation, aluminum intoxication, hyperparathyroidism, blood losses, or marrow dysfunction.' However, early estimation of the probability of response in a given patient would be of considerable interest. If a patient is identified as having a low probability of response with the initial dose, specific causes of possible treatment failure should be identified and corrected, or the dose should be increased rapidly to insure rapid elimination of transfusion requirements. On the other hand, if a patient is recognized as having a high probability of response to a relatively low starting dose, higher costs and possibly an increased incidence of side effects could be avoided.
We studied 64 hemodialysis patients receiving a relatively low starting dose ofrHuEpo and attempted to identify retrospectively early predictors of response among baseline as well as early changes of several laboratory parameters. The results show that baseline serum fibrinogen and transfemn receptor, as well as the early increment of serum transfemn receptor (as a marker of erythropoietic response), are useful predictors of response.
PATIENTS AND METHODS
We studied 64 consecutive patients, 33 men and 3 1 women, with the anemia of chronic renal failure who had been on hemodialysis for a mean time (M f SD) of 35 f 42 months (range 1 to 168 months). Mean age was 50 * 14 years. Their baseline Hct was 21.8% + 2.3% and they had required an average of 7 +-7 U (range 0 to 33 U) packed red blood cells in the preceding year. No patient was excluded on the basis of an hematologic disorder, iron deficiency, inflammation, aluminum intoxication, or hyperparathyroidism. There was no case of infection requiring parenteral antibi- otics at the time of study entry. RHuEpo was started at a dose of 50 U/kg/dose three times a week, intravenously, after hemodialysis. The dose was increased to 75 and 100 U/kg if no elevation of Hct was observed after 1 and 2 months, respectively. After a minimum follow-up of 6 months, response was evaluated as early response (Hct 2 30% without transfusion within 3 months), late response (Hct 2 30% without transfusion after 3 months), or failure (target Hct not reached). Oral or parenteral iron supplements were given when serum femtin was below 100 ng/mL. The study was approved by the ethical committee of the School of Medicine at the University of Ligge.
Patients.
Human placental receptortransferrin complex was purified as described elsewhere' and injected repeatedly into rabbits. Serum IgG was isolated from rabbit serum' and transferrin antibodies were removed by passing through a column of human difemc transferrin coupled to Affigel 15 (BioRad, Richmond, CA). Characterization of Serum TW and receptor antibody has been described elsewhere.lO."
An enzyme-linked immunosorbent assay (ELISA)" was used with minor modifications to measure serum levels of soluble TW (sTfR). Immunoplates I with certificate of quality (Nunc Intermed, Roskilde, Denmark) were used. The aliquots of blanks, standards, and unknown samples were added using a Digiflex automatic pipetor (Micromedic System, Philadelphia, PA). Standards were diluted to between 5 and 100 ng/mL and unknown sera were diluted 150 to 1:2,000 with 0. I5 mol/L phosphate-buffered saline (PBS) (pH 7.4) containing 0.5% bovine serum albumin (BSA) and 0.05% Tween 20. After color development, differential absorbance was read in dual wave length mode at 492 and 690 in a Titertek Multiskan MCC/340 plate reader (Flow Laboratories, Herts, England). In drawing the calibration curve, allowance was made for the molecular weight of the transferrin molecule included in the receptortransfemn complex by multiplying the protein content of the standard by 0.69. Each sample was run in triplicate. The between-assay variability (coefficient of variation) was 7.2% when the same control sample was measured in each plate.
Miscellaneous. Complete blood counts were determined in a Technicon H 1 cell counter (Tarrytown, NJ). Retic counts were obtained by an automated cytofluorometric method.'* Serum iron (SeFe) and total iron binding capacity (TIBC) were measured by standard methods.13 Serum ferritin was measured by radioimmunoassay.14 Circulating Epo levels were measured by a commercially available radioimmunoassay (Incstar Corp, Stillwater, MN). Predicted Epo values were determined for each Hct from the regression equation between log(Epo) and Hct in a reference group, and ratios of observed to predicted Epo values (O/P Epo) were calculated. 15 Statistical methods. Changes in Hct, reticulocyte, SeFe, transfemn saturation, serum ferritin, and serum TW values were d c ulated as percent change compared with baseline values. Student's t-tests, with pooled or separated variances as appropriate, were used to compare two groups. Analysis of variance (ANOVA), with Snedecor's F-test or Welch's test as appropriate, was used to compare more than two groups. Response rates in groups of patients were compared by Pearson chi-square tests. The univariate r correlation coefficient between two parameters was computed in least squares regression equation. Multivariate stepwise regression was also used for some dependent parameters. Time to complete response was studied by life table analysis, and Wilcoxon log rank tests were used for comparisons between groups. Time to complete response was also studied by multivariate analysis in the Cox model. Stepwise discriminant analysis (with a jackknife-validation procedure) was camed out between groups based on response. Most statistical analyses were done using programs ID, 2D, 3D, 7D, 4F, 1 R, 2R, 1 L, 2L, and 7M ofthe BMDP Statistical Software (University of California, Berkeley).
Transferrin receptor (TD) assay.
RESULTS
Among the 64 patients, 34 were early responders, 15 late responders, and 15 failures. Among failures, 5 increased their Hct more than 6 percentage points over baseline within (n = 3) or after (n = 2) 3 months of treatment (see comments below). Table 1 shows a retrospective analysis at baseline of failures, late responders, and early responders. Baseline TW, fibrinogen, and haptoglobin were highest in failures. Although late responders started with somewhat lower SeFe than early responders (P < .05), none of the other differences was statistically significant. Average Epo in failures was only 18 mU/mL after excluding one individual with a serum Epo value of 2 16 mU/mL. In addition, age, weight, duration of dialysis, previous transfusion needs, serum aspartate aminotransferase (SGOT), lactate dehydrogenase (LDH), bilirubin, alkaline phosphatase, urea, creatinine, vitamin B12, folate, and aluminum were not different among groups (data not shown in detail). Table 2 shows the distribution into failures, late responders, and early responders, of patient groups formed according to several clinical and biologic parameters. Because minimum follow-up was 6 months, life table analysis of time to response yielded very similar results in terms of percent total response. Among baseline parameters, lower serum TfR, fibrinogen, and haptoglobin, as well as higher serum protein, were significant (P < .05) predictors of response, whereas higher MCV, SeFe, and transferrin saturation, as well as lower serum Epo, carried marginal significance (P < .lo). Noticeably, the increase over baseline needed to reach target Hct was not determinant for the response rate, even between early and late responders. Furthermore, age, weight, duration of dialysis, serum SGOT, LDH, bilirubin, alkaline phosphatase, urea, creatinine, vitamin B,,, and folate, had no predictive value (data not shown in detail). Among parameters for which early changes were evaluated at day 14, TfR increment over baseline was significantly associated with response, whereas changes in retic count, Hct, SeFe, or transfemn saturation were not.
There was no correlation between an elevation of serum fibrinogen at the time of the study and the presence of an inflammatory underlying disease, systemic or local (eg, chronic pyelonephritis). Most patients with elevated fibrinogen maintained such levels throughout the observation penod.
There was a good inverse correlation between baseline TfR and femtin ( r = -.49, P < .001). Mean baseline TfR was 4,100 * 2,000 ng/mL in patients with femtin less than 100 ng/mL, 2,900 k 1290 ng/mL in those whose femtin was greater than 100 ng/mL but later dropped below this level, and 2,680 * 1,330 ng/mL in those in whom it remained always greater than 100 ng/mL (P Among the 8 patients who had baseline TW greater than 3,500 ng/mL and maintained serum femtin levels greater than 100 ng/mL, 4 responded to iron supplements (func- tional iron deficiency) and 4 did not receive iron and were treatment failures.
In multivariate analysis of time to complete response (Hct 2 30% without transfusion) by the Cox model, using baseline TfR, fibrinogen, haptoglobin, total protein, O/P Epo, SeFe, MCV, as well as day 14 TfR increment as covariates, only TfR increment ( P < .0002 for improvement in chi-square) and baseline fibrinogen ( P < .05) and O/P Epo ( P < .05) were entered into the model. When TfR increment was not considered, baseline TfR (P < .002), haptoglobin (P < .005) and MCV ( P < .lo) were the only variables entered.
When covariates were categorical variables (with cutpoints as used in table 2), again only baseline TfR ( P < .005) and fibrinogen ( P < .002) were entered into the model.
In stepwise discriminant analysis using various combinations of baseline parameters and early changes, only baseline fibrinogen and TfR (or TfR increment over baseline) were entered into the model. The rate of correct classification into responders and failures was 84% with baseline fibrinogen and TfR, and 76% with baseline fibrinogen and TfR increment. Only 2 early responders were not classified correctly: one had an elevated serum fibrinogen that corrected rapidly, the other had no TfR increase after 2 weeks because early iron supplements corrected functional iron deficiency.
Based on these results, we constructed two simple predictive models useful in clinical practice. The first model (Fig  1) was established only on baseline parameters fibrinogen and TW: 100% (89% early and 1 1% late) response rate when both parameters were low, versus only 29% (all late) when both were high, versus 67% (39% early and 28% late) when one was low and the other one high (P < .001 for comparison among all 3 groups). The second model (Fig 2) included the early TfR increment as well. When TW increment was r20%, the response rate was 96%. When TfR increment was less than 20%, the response rate was 100% (all early) when baseline TfR and fibrinogen were low, versus 12% (all late) when fibrinogen was elevated, and versus 62% (38% early and 24% late) when fibrinogen was low but baseline TfR high (P < .001 for comparison among all 4 groups). Three responding patients had this pattern of TW increment less than 20% despite baseline TW less than 3,500 ng/mL and fibrinogen less than 4 g/L. This remained unexplained in one patient with a TW increment of 13%. The other two were iron deficient, received iron supplements from the beginning, and had low TW increments because correction of iron status tended to lower TfR levels.
The major reason for late response or failure was identified in each patient and included inflammation (elevated serum fibrinogen, n = 13), iron deficiency (serum ferritin < 100 ng/mL at any time, n = 4), functional iron deficiency (serum ferritin >lo0 ng/mL but iron-responsive, n = 4), erythroid marrow disorders (myelofibrosis or a myelodysplastic syndrome, n = 4), red blood cell loss (hemolysis or bleeding, n = 3), and inadequate Epo dosage (because of a history of seizures or severe hypertension, n = 2). Among patients with baseline ferritin less than 100 ng/mL (all received iron supplements), 9 were early responders, 1 was a late responder, and 4 were failures (one had myelofibrosis, one a myelodysplastic syndrome, and one inflammation). The 3 patients with red blood cell loss should have been early responders by all criteria tested alone or in multivariate fashion, but red blood cell loss prevented them from rapidly reaching the target Hct. One reached target Hct on day 120 after an acute bleeding episode, and among the other 2 with autoimmune hemolytic anemia, 1 reached target Hct on day 140 and the other eliminated transfusion requirements without achieving target Hct. The 2 patients who received low doses of rHuEpo also should have been early responders by all criteria, and indeed increased their Hct more than 6 percentage points within 3 months.
DISCUSSION
rHuEpo has been shown to be very effective in correcting the anemia of endstage renal d i~e a s e .~,~.~ Although 95% of the patients will respond to high doses of rHuEpo, response is much more variable with doses in the range of 40 to 50 U/kg, intravenously, thrice weekly. Furthermore, many
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From clinical trials reporting a high response rate included only patients with no absolute (serum femtin <lo0 ng/mL) or relative (transfemn saturation <20%) iron deficiency, inflammatory disorder, hemolysis, blood loss, hematologic disease, or other diseases that might impair response.' Some of the latter patients might benefit from rHuEpo if treatment could be tailored to their need. Therefore, we examined response to rHuEpo in an unselected population of hemodialysis patients from a single center, without excluding patients with characteristics potentially affecting re- When both were low, the response rate was 100% (89% early and 1 1 % late), when both were high, 29% (all late), and when one was low and the other one high, 67% (39% early and 28% late).
sponse to rHuEpo. Patients were classified as early responders (target Hct by day 90), late responders (target Hct after day 90), or failures (target not reached). Using various statistical methods, we found that baseline fibrinogen and TfR as well as the early TfR increment were useful predictors of response to rHuEpo. Therefore, we developed a simple predictive model based on these parameters. When the 2-week TfR increment was over 20% or when both baseline TfR and fibrinogen were low, response rates were in excess of 95%. When TfR increment was low and baseline fibrinogen elevated, virtually no response was observed. When TfR increment was low but baseline fibrinogen low and baseline TfR high, response rate was in the range of 60%. Using pretreatment parameters only, the response rate was 100% (89% early and 11% late) when both TfR and fibrinogen were low, versus 29% (all late) when they were both high, and 67% (39% early and 28% late) when one was low and the other high. Therefore, simple laboratory parameters can provide early recognition of the probability of response to rHuEpo.
Other parameters have been studied as predictors of response to rHuEpo. The elevation of the absolute reticulocyte count and of the percentage of highly fluorescent reticulocytes after a single administration of rHuEpo has also been found to be somewhat predictive.16 However, in our study, the early increment of reticulocyte count had absolutely no predictive value. Peripheral blood burst-forming units-erythroid (BFU-E) increase significantly within I week of treatment with rHuEpo.I7 It has been shown that the individual response to rHuEpo correlated with the initial number of peripheral blood BFU-E as well as their increase after one week of treatment." However, no clear cutpoint value could be proposed and BFU-E assays take 14 days to perform and are not widely available at dialysis centers. Recently, we also showed that among patients with hematologic malignancies treated with rHuEpo, the most likely ones to respond were those with a consistent increase (250%) of TfR levels after 2 weeks of treatment.19 Both TfR and the erythron transfemn uptake (ETU), a ferrokinetic measurement of erythropoiesis, increase in response to rHuEpo in a dose related fa~hion.~,~',~' All these results indicate that the early erythropoietic response to rHuEpo is a good indicator of the later hematologic response and that serum TfR is probably the best parameter to monitor these early changes of erythropoietic activity.
The importance of iron status for rHuEpo has long been r e~o g n i z e d .~.~,~~ Although a serum femtin level of less than I2 ng/mL defines absolute iron deficiency in normal individual~,'~ there is no such clear-cut value for renal failure patient^,'^'^^ probably in part because inflammation associated with the release of certain cytokines (such as interleukin-1) during dialysis may produce misleading elevations of femtin levels.2722s Therefore, femtin levels less than 30 or 100 ng/mL are usually considered indicative of insufficient iron stores, particularly in the context of treatment with rHuEpo. In our series, a serum femtin level less than 100 ng/mL did not prevent a rapid response to rHuEpo, provided iron deficiency was recognized and adequate iron supplements were given. Besides absolute iron deficiency, relative or functional iron deficiency, ie, iron-deficient erythropoiesis in the presence of appropriate iron stores, may be encountered. It is usually considered that relative iron deficiency is present when transfemn saturation decreases below 16% or 20%. However, the value of transfemn saturation in patients with renal failure appears less consistent.25%29.30 In our study, transferrin saturation was not different among early responders, later responders, and failures, neither before nor during treatment with rHuEpo. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From by determining the percentage of hypochromic and microcytic red blood cells in circulation, which shows only a loose inverse correlation with transferrin saturation." Iron-deficient erythropoiesis can also be recognized by an elevation of serum TfR3* and this could be the reason why patients with baseline TfR level greater than 3500 ng/mL were less likely to respond well to rHuEpo. Functional iron deficiency could probably be best evidenced by a poor response to rHuEpo in the presence of adequate iron stores, but a brisk response when iron supplements are given.33 This was indeed observed in several of our patients. As iron absorption in hemodialysis patients appears appropriate for the status of iron stores,24 a simple way to overcome this problem is to give oral iron supplements to all patients, except those with evident iron overload.
The explanation for late response or failure was inflammation in the majority of the patients. Infection has been recognized as a cause of blunted response to erythr~poietin,~ but we found that even a low degree of clinically occult inflammation may be responsible for a relative impairment of response. Such an elevation of serum fibrinogen was one of the best predictors of response. It is possible that higher doses of rHuEpo could overcome the relative resistance of patients with inflammation, as has been shown for anemic patients with rheumatoid arthritis.34 However, it is important to recognize occult inflammation because, in many cases, it is correctable with the appropriate treatment and the additional costs associated with dose escalation can thus be avoided.
The presence of erythropoiesis inhibitors has been implicated in the pathogenesis of the anemia of chronic renal failure and could possibly impair response to rHuEpo. However, no evidence of such inhibitors has been found in careful s t~d i e s . '~,~' ,~~ Although aluminum intoxication might blunt response by interfering with heme synthesi~,~~.~' we did not find any difference according to serum aluminum levels. Secondary hyperparathyroidism can induce marrow fibrosis and impair response to r H~E p o .~* However, with the exception of a patient with myelofibrosis in whom parathyroid hormone was moderately elevated, there was no evidence of decreased erythroid response to rHuEpo in patients with increased parathyroid hormone levels ( Table 2) and baseline values were similar in early responders, late responders, and failures (Table 1) . However, average parathormone levels were well below those associated with poor response to r H~E p o .~' The main cause for failure or late response was marrow myelofibrosis or a myelodysplastic syndrome in 4 patients. It is possible that higher doses of rHuEpo could produce better responses in these patients, but in most cases only ineffective erythropoiesis would be ~timulated.'~ Bleeding or hemolysis could prevent optimal response even when red blood cell production is adequately stimulated by rHuEpo. This was the reason for failure or late response in 3 of our patients. Occasionally, as in 2 of our patients, rHuEpo will not be given in appropriate doses because of the fear of severe hypertension or seizures.
In conclusion, we have shown that response to relatively low doses of rHuEpo can be predicted early in the course of treatment by using baseline serum TfR and fibrinogen as well as the 2-week increment of TfR level. Early recognition of a low probability of response in a given patient can help identify and correct specific causes of treatment failure such as inflammation, iron deficiency, or marrow disorders. Alternatively, in patients with a low probability of response to the starting dose but with no correctable cause offailure, the dose of rHuEpo could be increased early in the course of treatment without waiting for an evaluation of hematologic response after I or 2 months.
